• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服米替福新对T细胞缺陷小鼠实验性内脏利什曼病治疗后复发的抑制作用

Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.

作者信息

Murray H W

机构信息

Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA.

出版信息

Antimicrob Agents Chemother. 2000 Nov;44(11):3235-6. doi: 10.1128/AAC.44.11.3235-3236.2000.

DOI:10.1128/AAC.44.11.3235-3236.2000
PMID:11036063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC101643/
Abstract

T-cell-deficient nude mice infected with Leishmania donovani were treated with miltefosine and then given either no treatment or intermittent miltefosine. Intracellular visceral infection recurred in untreated mice but was suppressed by once- or twice-weekly oral administration of miltefosine. Miltefosine may be useful as oral maintenance therapy for T-cell-deficient patients with visceral leishmaniasis.

摘要

感染杜氏利什曼原虫的T细胞缺陷型裸鼠接受了米替福新治疗,之后一部分未再接受治疗,另一部分接受间歇性米替福新治疗。未治疗的小鼠体内内脏感染复发,但每周口服一次或两次米替福新可抑制感染。米替福新可能作为内脏利什曼病T细胞缺陷患者的口服维持疗法。

相似文献

1
Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.口服米替福新对T细胞缺陷小鼠实验性内脏利什曼病治疗后复发的抑制作用
Antimicrob Agents Chemother. 2000 Nov;44(11):3235-6. doi: 10.1128/AAC.44.11.3235-3236.2000.
2
Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.十六烷基磷酸胆碱(米替福新)对T细胞缺陷及活化巨噬细胞杀菌机制缺陷小鼠的内脏利什曼原虫杀灭活性。
J Infect Dis. 2000 Feb;181(2):795-9. doi: 10.1086/315268.
3
[Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].[内脏利什曼病的治疗:米替福新的疗效与局限性]
Sante. 2001 Oct-Dec;11(4):257-8.
4
Oral combination of eugenol oleate and miltefosine induce immune response during experimental visceral leishmaniasis through nitric oxide generation with advanced cytokine demand.油酸丁香酚酯和米替福新联合口服在实验内脏利什曼病中通过一氧化氮生成和高级细胞因子需求诱导免疫反应。
Cytokine. 2021 Oct;146:155623. doi: 10.1016/j.cyto.2021.155623. Epub 2021 Jun 16.
5
Effect of Pam3Cys induced protection on the therapeutic efficacy of miltefosine against experimental visceral leishmaniasis.Pam3Cys 诱导保护对米替福新治疗实验内脏利什曼病疗效的影响。
Peptides. 2011 Oct;32(10):2131-3. doi: 10.1016/j.peptides.2011.09.014. Epub 2011 Sep 19.
6
Oral miltefosine in the treatment of kala-azar.口服米替福新治疗黑热病
Natl Med J India. 2000 Jul-Aug;13(4):202-3.
7
Leishmania resistance to miltefosine associated with genetic marker.利什曼原虫对米替福新的耐药性与遗传标记有关。
Emerg Infect Dis. 2012 Apr;18(4):704-6. doi: 10.3201/eid1804.110841.
8
Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.米替福新治疗内脏利什曼病后的复发与感染的利什曼原虫株的传染性增加有关。
mBio. 2013 Oct 8;4(5):e00611-13. doi: 10.1128/mBio.00611-13.
9
Oral miltefosine for Indian visceral leishmaniasis.口服米替福新治疗印度内脏利什曼病。
N Engl J Med. 2002 Nov 28;347(22):1739-46. doi: 10.1056/NEJMoa021556.
10
Persistent dermal lesions in a patient with previous history of visceral leishmaniasis.一名曾患内脏利什曼病的患者出现持续性皮肤病变。
Parasitol Int. 2021 Feb;80:102197. doi: 10.1016/j.parint.2020.102197. Epub 2020 Sep 11.

引用本文的文献

1
Oral treatment with T6-loaded yeast cell wall particles reduces the parasitemia in murine visceral leishmaniasis model.口服负载 T6 的酵母细胞壁颗粒治疗可降低小鼠内脏利什曼病模型中的寄生虫血症。
Sci Rep. 2019 Dec 27;9(1):20080. doi: 10.1038/s41598-019-56647-w.
2
Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.利什曼病化疗中的治疗转换:针对未满足治疗需求的独特方法。
J Parasit Dis. 2011 Oct;35(2):104-12. doi: 10.1007/s12639-011-0040-9. Epub 2011 May 20.
3
In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.醚脂质埃达福林对利什曼原虫属和 SbV 耐药寄生虫的体外和体内疗效。
PLoS Negl Trop Dis. 2012;6(4):e1612. doi: 10.1371/journal.pntd.0001612. Epub 2012 Apr 10.
4
The relationship between leishmaniasis and AIDS: the second 10 years.利什曼病与艾滋病的关系:第二个十年
Clin Microbiol Rev. 2008 Apr;21(2):334-59, table of contents. doi: 10.1128/CMR.00061-07.
5
Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.米替福新影响杜氏利什曼原虫前鞭毛体的脂质代谢。
Antimicrob Agents Chemother. 2007 Apr;51(4):1425-30. doi: 10.1128/AAC.01123-06. Epub 2007 Jan 22.
6
Miltefosine (Impavido): the first oral treatment against leishmaniasis.米替福新(Impavido):第一种治疗利什曼病的口服药物。
Med Microbiol Immunol. 2004 Nov;193(4):173-80. doi: 10.1007/s00430-003-0201-2. Epub 2003 Sep 26.
7
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.十六烷基磷酸胆碱(米替福新)对克氏锥虫耐药菌株的促炎和细胞毒性作用。
Antimicrob Agents Chemother. 2002 Nov;46(11):3472-7. doi: 10.1128/AAC.46.11.3472-3477.2002.
8
Clinical and experimental advances in treatment of visceral leishmaniasis.内脏利什曼病治疗的临床与实验进展
Antimicrob Agents Chemother. 2001 Aug;45(8):2185-97. doi: 10.1128/AAC.45.8.2185-2197.2001.

本文引用的文献

1
Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.内脏利什曼病(黑热病)的治疗:十年进展与未来方法
Int J Infect Dis. 2000;4(3):158-77. doi: 10.1016/s1201-9712(00)90078-x.
2
Kala-azar as an AIDS-related opportunistic infection.黑热病作为一种与艾滋病相关的机会性感染。
AIDS Patient Care STDS. 1999 Aug;13(8):459-65. doi: 10.1089/108729199318183.
3
Oral treatment of visceral leishmaniasis with miltefosine.
Ann Trop Med Parasitol. 1999 Sep;93(6):589-97. doi: 10.1080/00034989958096.
4
Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.十六烷基磷酸胆碱(米替福新)对T细胞缺陷及活化巨噬细胞杀菌机制缺陷小鼠的内脏利什曼原虫杀灭活性。
J Infect Dis. 2000 Feb;181(2):795-9. doi: 10.1086/315268.
5
Visceral leishmaniasis (kala-azar) in solid organ transplantation: report of five cases and review.
Clin Infect Dis. 1999 Oct;29(4):918-21. doi: 10.1086/520457.
6
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.米替福新,一种口服药物,用于治疗印度内脏利什曼病。
N Engl J Med. 1999 Dec 9;341(24):1795-800. doi: 10.1056/NEJM199912093412403.
7
Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.HIV 感染患者内脏利什曼病的治疗:一项比较葡甲胺锑酸盐与两性霉素 B 的随机试验。西班牙 HIV-利什曼病研究小组。
AIDS. 1999 Jun 18;13(9):1063-9. doi: 10.1097/00002030-199906180-00009.
8
Trial of oral miltefosine for visceral leishmaniasis.口服米替福新治疗内脏利什曼病的试验。
Lancet. 1998 Dec 5;352(9143):1821-3. doi: 10.1016/S0140-6736(98)04367-0.
9
Visceral leishmaniasis in patients infected with the human immunodeficiency virus.感染人类免疫缺陷病毒患者的内脏利什曼病
Eur J Clin Microbiol Infect Dis. 1997 Dec;16(12):898-903. doi: 10.1007/BF01700556.
10
Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy.意大利西西里岛内脏利什曼病的流行病学监测
Am J Trop Med Hyg. 1997 Jul;57(1):75-8. doi: 10.4269/ajtmh.1997.57.75.